320 related articles for article (PubMed ID: 14713257)
1. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
3. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
de Herder WW; Lamberts SW
Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
7. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptors in gut endocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Baillieres Clin Gastroenterol; 1996 Dec; 10(4):571-87. PubMed ID: 9113313
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
[TBL] [Abstract][Full Text] [Related]
10. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
11. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
13. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
15. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
17. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues.
Reubi JC; Laissue J; Waser B; Horisberger U; Schaer JC
Ann N Y Acad Sci; 1994 Sep; 733():122-37. PubMed ID: 7978860
[TBL] [Abstract][Full Text] [Related]
18. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.
O'Toole D; Saveanu A; Couvelard A; Gunz G; Enjalbert A; Jaquet P; Ruszniewski P; Barlier A
Eur J Endocrinol; 2006 Dec; 155(6):849-57. PubMed ID: 17132755
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
20. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
